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Abstract: Protein cage nanoparticles have the potential to serve as multifunctional cell targeted, 
imaging and therapeutic platforms for broad applications in medicine. However, before they ﬁ  nd 
applications in medicine, their biocompatibility in vivo needs to be demonstrated. We provide 
here baseline biodistribution information of two different spherical protein cage nanoplatforms, 
the 28 nm viral Cowpea chlorotic mottle virus (CCMV) and the 12 nm heat shock protein (Hsp) 
cage. In naïve and immunized mice both nanoplatforms show similar broad distribution and 
movement throughout most tissues and organs, rapid excretion, the absence of long term persis-
tence within mice tissue and organs, and no overt toxicity after a single injection. These results 
suggest that protein cage based nanoparticles may serve as safe, biocompatible, nanoplatforms 
for applications in medicine.
Keywords: protein cage nanoparticles, Cowpea chlorotic mottle virus, heat shock protein, 
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Background
The use of nanoparticles in medicine holds the promise to provide dramatic 
improvements in diagnosis, imaging, and treatment of human disease and disorders 
(Brigger et al 2002; Emerich and Thanos 2003; Wickline and Lanza 2003; Allen and 
Cullis 2004; Service 2005a, 2005b). However, before this becomes a reality, there is 
a need for a thorough evaluation of nanoparticle toxicity and biodistribution in vivo. 
Although there are numerous reports promoting various nanoplatforms (5–100 nm) for 
medicine, few of them have been well characterized in vivo. Nanoparticles inherently 
have varying biological behaviors dependent on their size, shape, composition, surface 
chemistry, and associated physical properties. These attributes can greatly inﬂ  uence 
deposition, clearance from the body, and the toxicological nature of the nanoparticle 
(Powers et al 2006). There is a growing concern among scientists and the general 
public about the potential toxicity and biocompatibility of nanoplatforms (Nel et al 
2006). At this time, a high priority must be placed on a more complete understanding 
of the circulation, clearance rates, blood half-life, stability, immunogenicity and organ 
biodistribution of nanoparticle delivery vehicles with the main goal of improving the 
functionality of nanoparticles in the biological environment so as to fully realize their 
biomedical value (Kayser et al 2005; Moghimi et al 2005).
Naturally occurring and synthetic nanometer scaled structures have the potential to 
be utilized as tissue and organ targeted cell-speciﬁ  c imaging and therapeutic delivery 
systems. There are a diversity of nanometer scale platforms being developed for such bio-
medical applications including: liposomes (Lee and Low 1995; Muller et al 2001; Barratt 
2003), micelles (Roy et al 2003), polyamidoamine (PAMAM) dendrimer clusters (Choi 
et al 2005; Gurdag et al 2006), poly (D, L-lactic-co-glycolic acid) [PLGA] nanoparticles International Journal of Nanomedicine 2007:2(4) 716
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(Yoo et al 1999, 2000), hydrogel dextran nanoparticles (Jana 
et al 2002; Na and Bae 2002), polysaccharide nanoparticles 
(Janes et al 2001), polyalkylcyanoacrylate nanocapsules 
(Damge et al 1988), lipid nanoparticles (Fundaro et al 2000), 
metal nanoshells (Loo et al 2004, 2005), amphiphilic core-shell 
nanoparticles (Sun et al 2005), viruses (Douglas and Young 
1998; Flenniken 2004; Singh et al 2006) and other protein 
cage-based nanostructures (Hooker et al 2004).
The most extensively investigated nanoplatforms in 
terms of their in vivo biodistribution and toxicity are the 
nano materials commonly referred to as quantum dots 
(QDs) (Hardman 2006). Quantum dots are semiconduc-
tor nanocrystals (∼2–100 nm) with distinctive optical and 
electrical characteristics (Bruchez et al 1998). Structurally, 
QDs consist of a metalloid crystalline core and a “cap” or 
“shell” that shields the core and renders the QD bioavail-
able. The QDs are “functionalized,” or given secondary 
coatings, which improves water solubility, QD core durabil-
ity, and assigns a desired bioactivity such as cell targeting. 
While more detailed studies remain to be performed, past 
studies have suggested a high degree of variability in QD 
biodistribution and toxicity in animal model systems that 
is likely dependent on multiple factors. These factors may 
include inherent physicochemical properties and environ-
mental conditions including QD size, charge, concentration, 
outer coating bioactivity (capping material and functional 
groups), and oxidative, photolytic, and mechanical stability. 
This variability has suggested to some that under certain 
conditions QDs may pose environmental and human health 
risks (Hardman 2006). There is clearly a need to investigate 
the biodistribution of additional nanostuctures in order to 
expand our understanding of the compatibility of nanopar-
ticles for application in medicine.
Viruses, virus-like particles (VLPs), and other protein 
cage nano architectures provide alternative platforms for 
combined cell-targeted imaging and therapeutic delivery 
systems. Protein cage systems that are currently being devel-
oped for biomedical applications share the common property 
of being assembled from a limited number of subunits to 
form a closed structure that deﬁ  nes an interior environment 
capable of housing therapeutic or imaging agents and an 
exterior surface capable of multivalent presentation of cell 
targeting ligands. Examples of spherical viruses, VLPs, 
and cellular protein cage architectures being explored for 
biomedical applications include the Cowpea chlorotic 
mottle virus (CCMV) (Speir et al 1995; Gillitzer et al 2002, 
2006; Brumﬁ  eld et al 2004), Cowpea mosaic virus (CPMV) 
(Brennan et al 2001; Chatterji et al 2002; Raja et al 2003; 
Blum et al 2004; Rae et al 2005; Lewis et al 2006), ferritins 
(Allen et al 2002), Dps-like protein cages (Wiedenheft et 
al 2005; Ramsay et al 2006) and small heat shock protein 
cages (Flenniken et al 2003, 2005, 2006; Kim et al 1998a, 
1998b). Qualitative biodistribution studies with ﬂ  uorescently 
labeled CPMV in mice and chick embryos indicate distribu-
tion of the particles in various tissues (ie, spleen, kidney, 
liver, lung, stomach, small intestine, lymph nodes, bone 
marrow, vascular endothelium and brain) after intravenous 
administration (Rae et al 2005; Lewis et al 2006). However, 
a quantitative study of protein-based nanoparticles has not 
been reported.
We present here quantitative bio-distribution and 
immunogenicity of two nanometer scale protein cage archi-
tectures; speciﬁ  cally, the plant virus based CCMV (Speir 
et al 1995; Gillitzer et al 2002; Brumﬁ  eld et al 2004) and a 
small heat shock protein (Hsp) architecture originally iso-
lated from the hyperthermophilic archaeon Methanococcus 
jannaschii (Kim et al 1998a). These two nanometer scale 
protein cage architectures have been genetically and chemi-
cally modiﬁ  ed toward their development as potential cell 
targeted therapeutic and imaging agent delivery systems 
(Gillitzer et al 2002, 2006; Flenniken et al 2003, 2005; Allen 
et al 2005). Cowpea chlorotic mottle virus is a member of the 
Bromoviridae family (Francki 1985). Its capsid is composed 
of 180 copies of the coat protein which can self- assemble 
without packaging its viral genome to form an icosahedral 
particle with an exterior diameter of 28 nm and an interior 
diameter of 24 nm (Brumﬁ  eld et al 2004). Genetic and 
chemical modiﬁ  cation of CCMV has been used to impart 
cell targeting and imaging capacity to the protein cage 
architecture (Gillitzer et al 2002, 2006). The Hsp assembles 
into an empty 24 subunit cage with octahedral symmetry that 
has an exterior diameter of 12 nm and an interior diameter 
of 6.5 nm (Kim et al 1998a, 1998b). The overall structure of 
Hsp resembles a multi-windowed hollow sphere. The Hsp 
cages have been derivatized with therapeutic molecules and 
a genetic variant, HspG41C-RGD4C, has been shown to 
bind melanoma cells in vitro (Flenniken et al 2003, 2005, 
2006). We report the in vivo biodistribution and clearance 
of non-targeted CCMV and the Hsp protein cages in both 
naïve and immunized mice.
Methods
Puriﬁ  cation and characterization
of HspG41C
Cloning, mutagenesis, and puriﬁ  cation of the heat shock 
protein (Hsp) cage from an E. coli heterologous expression International Journal of Nanomedicine 2007:2(4) 717
Biodistribution of protein cage nanoparticles
system was previously described (Flenniken et al 2003). 
The HspG41C cages, with interior exposed thiols, were 
characterized by size exclusion chromatography (Superose-6, 
Amersham-Pharmacia), dynamic light scattering (DLS) 
90 plus (Brookhaven Instruments), and by transmission 
electron microscopy (TEM) (LEO 912 AB) (Supplemental 
Figure 1).
Puriﬁ  cation and characterization 
of CCMV S102C and CCMV K42R
Two genetic variants of CCMV were utilized for these experi-
ments, CCMV S102C for epiﬂ  uorescence studies and CCMV 
K42R for biodistribution studies. Puriﬁ  cation of CCMV 
S102C from the Pichia pastoris (yeast) heterologous expres-
sion system was performed as previously described (Speir 
et al 1993; Brumﬁ  eld et al 2004). The primer sequences uti-
lized for PCR mediated mutagenesis of CCMV S102C were: 
S102C for 5′ gttgcttcccagtgtttgtggtaccgtgaaatcctgtg 3′ and 
S102C rev 5′ cacaggatttcacggtaccacaaacactgggaagcaac 3′. 
The integrity of the entire CCMV S102C coding sequence 
was conﬁ  rmed by sequencing on an ABI 310 automated 
capillary sequencer using Big Dye chain termination 
sequence technology (Applied Bio Systems, Foster City, 
CA, USA). The CCMV S102C capsids were puriﬁ  ed and 
characterized by size exclusion chromatography (Superose 
6, Amersham-Pharmacia), dynamic light scattering (DLS) 
90 plus (Brookhaven Instruments), and transmission electron 
microscopy (TEM) (LEO 912 AB) (Supplemental Figure 1). 
CCMV K42R capsids were characterized (Fox et al 1996) 
and puriﬁ  ed from plants as previously described (Bancroft 
and Hiebert 1967).
Derivatization of CCMV S102C and 
HspG41C with Texas Red®C2-maleimide 
(Invitrogen)
Cysteine containing genetic variants, CCMV S102C 
and HspG41C, were chemically derivatized with Texas 
Red®C2-maleimide (Invitrogen) using methods described 
in (Gillitzer et al 2002; Flenniken et al 2003). The cages 
(100 mM HEPES 50 mM NaCl pH 6.5) were reacted with 
Texas Red®C2-maleimide (Invitrogen) in a concentration of 
3-fold molar excess per subunit. The reactions proceeded 
for 30 minutes at room temperature followed by overnight 
incubation at 4 °C. Texas-Red® labeled cages were puriﬁ  ed 
from free dye by size exclusion chromatography (Superose 
6, Amersham-Pharmacia) in Dulbecco’s phosphate buffered 
saline pH 7.4.
Iodination of protein cages (CCMV K42R 
and HspG41C)
Protein cages were iodinated utilizing IODO-BEADS Iodin-
ation Reagent (Pierce) according to manufacturer’s instruc-
tions. Unincorporated 125I were removed with desalting 
columns (Zeba Desalt Spin Columns, Pierce): two rounds 
of desalting were performed. The iodinated protein 
cages was characterized by absorbance spectroscopy, 
size exclusion chromatography (Superose 6, Amersham 
Pharmacia), dynamic light scattering (Brookhaven 90Plus), 
and transmission electron microscopy (TEM) (Leo 912 
AB) (Supplemental Figure 1). The speciﬁ  c activity of 125I 
labeled protein cages was determined from counts associ-
ated with the sample compared to a linear regression ﬁ  t to 
the counts from 125I standards (ranging from 0–1000 nCi) 
(x-axis) plotted with their corresponding counts per minute 
(y-axis) (Beckman Gamma 4000 Counting System). Typi-
cally, speciﬁ  c activity for Hsp cage samples was ~20 nCi/μg 
and ~250 nCi/μg for CCMV samples. The incorporation 
of  125I, in terms of speciﬁ  c activity (nCi/μg), was about 
10-fold greater in CCMV K42R as compared to HspG41C 
cages. This discrepancy is most likely because CCMV has 
more surface accessible tyrosines (5 per subunit; 900 per 
cage; exterior Tyr 50, 157, 159, 190, interior Tyr 138) than 
Hsp (2 per subunit; 48 per cage; interior Tyr 96, subunit 
interface Tyr 106).
In vivo biodistribution experiments with 
125I-HspG41C or 125I-CCMV nanoparticles
Mice received an intravenous dose, via the tail vein, of either 
50 μg of 125I-HspG41C or 125I-CCMV cage in a 200 μL 
volume. The dose of radiation ranged from approximately 
0.3 to 0.5 μCi of cage. The nanocages were allowed to 
circulate for 1 to 24 hours before animals were sacriﬁ  ced 
with a lethal dose of sodium pentobarbital. When a lack 
of pedal response was apparent mice were opened and 
the abdominal aorta clipped. A 70 μL blood sample was 
obtained and all organs excised and weighed separately. 
The blood, tissue and injected dose samples were then 
transferred into vials and counted on a Beckman Gamma 
4000 Counting System.
Calculations of radioactivity in blood
and organ samples
Tissue radioactivity measures were in counts-per-minute (cpm) 
and background adjusted. The percent of recovered dose per 
gram of tissue or per organ was calculated as follows:International Journal of Nanomedicine 2007:2(4) 718
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% of injected dose/g of tissue
Activity recovered/g of tissue
A
=
d dministered dose radioactivity
×100
% of injected dose/organ
Activity recovered/organ
Administer
=
e ed dose radioactivity
×100
In order to compare the burden of deposition in various 
organs the percent of injected dose per gram of tissue was 
used. However, some tissues weigh less than 1 gram and 
result in percentages greater than 100. The percent injected 
dose/organs, urine and feces samples were totaled for mice 
at 1 and 24 hours so as to determine the total percent of dose 
recovered in each experiment.
Animals
The experimental animal protocol used for all studies includ-
ing the 125I trials was approved by the Institutional Animal 
Care and Use Committee and the Safety and Risk Manage-
ment Ofﬁ  ce at Montana State University. Female BALB/c 
mice, 10–14 weeks old, weighing on average 18–22 gm each, 
were purchased from Charles River Laboratories (Wilm-
ington, MA). The 24 hour mice were housed in Nalgene® 
Metabolic Cage for Single Mouse (Rochester, NY) under 
normal conditions with ad libitum access to ﬁ  nely ground 
sterilized rodent chow and water.
Immunizations
Female BALB/c mice were immunized with either a 50 μg 
HspG41C or CCMV protein dose intravenously injected into 
the tail vein. Mice received the dose in a 200 μL volume at 
week 1 and two weeks later (week 3). At week 4 a blood 
sample was obtained to conﬁ  rm immunization and then week 
5 mice received an IV challenge of 50 μg of 125I-labeled cage 
to determine particle biodistribution as stated below.
SDS-polyacrylamide gel electrophoresis
Samples were run using SDS-Polyacrylamide Gel Elec-
trophoresis (PAGE) under denaturing conditions with 
TR-CCMV S102C and TR-HspG41C controls. Gels were 
visualized ﬁ  rst by ﬂ  uorescence (inverted image; Molecular 
Imager FX, BioRad) and then by Coomassie Brilliant Blue 
staining and compared to molecular weight markers.
Vibratome sections and ﬂ  uorescent 
microscopy
Mouse lungs were instilled with 3% low melt agarose (kept 
at 37 °C) and allowed to set-up in cold PBS for later section-
ing. One-hundred micron thick agarose lung sections were 
cut on a Leica VT1000S vibrating-blade microtome (Leica 
Microsystems Nussloch GmbH, Germany). Fresh kidney 
and liver cuts (100 microns thick) were also made using the 
vibrating microtome; these tissues samples were not agarose 
ﬁ  lled. Tissue sections were wet mounted on slides, cover 
slipped and viewed with the Nikon Eclipse E800 microscope 
(Nikon, Inc., Melville, NY) and imaged using the Nikon 
Digital Camera DXM1200 and MetaVue software (Molecu-
lar Devices Corporation, Downingtown, PA).
Hematoxylin and eosin staining
A morphological examination of lung, liver, spleen and 
kidney was conducted with tissues obtained from mice sensi-
tized and challenged with either of HspG41C or CCMV cage 
protein. The organs were excised from mice at 1 and 24 hrs 
after the challenge and ﬁ  xed in 10% phosphate-buffered 
formalin (Fisher Scientiﬁ  c), dehydrated in a graded series of 
ethanol, embedded in parafﬁ  n, and cut into 5 micron thick 
serial sections. Sections were then stained using hematoxy-
lin and eosin (H and E), and the morphology of the various 
tissues examined using the Nikon Eclipse E800 microscope 
and images taken with the Nikon Digital Camera DXM1200 
and MetaVue software as stated above.
Measurement of IgG and IgE cage speciﬁ  c 
antibodies
Total IgG specific HspG41C and CCMV in sera was 
measured by direct enzyme-linked immunosorbent assay 
(ELISA). The sera were kept frozen at –80 °C before analysis. 
Each well of a 96-well polystyrene plate was coated with 50 
μL of either a CCMV or Hsp solution at a protein concentra-
tion of 0.5–1.0 μg/mL and incubated overnight at 4 °C. The 
plate was then washed four times with a 2% horse serum 
solution prior to each well being blocked with 100 μL of a 
non-speciﬁ  c binding site blocking buffer (1% bovine serum 
albumin in PBS) and again incubated for two hours at room 
temperature. The plate was washed once more with the 2% 
horse serum solution and 100 μL of serum diluted in blocking 
buffer was added and the plate incubated for 2 hours at room 
temperature. The plate received four additional washes and 
100 μL per well of goat anti-mouse peroxidase conjugated 
IgG, diluted in blocking buffer to a 1:500 concentration, was 
added then incubated for one hour at room temperature. The 
samples were again washed four times and ABTS substrate 
added, allowed to react for 15 minutes and visualized at 
415 nm on a microplate reader (VERSAMAX Microplate 
Reader, Molecular Devices, Sunnyvale, CA, USA).International Journal of Nanomedicine 2007:2(4) 719
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Sera cage speciﬁ  c IgE was also measured by an ELISA 
assay. An afﬁ  nity puriﬁ  ed anti-mouse IgE capture mAb 
(2 μg/mL; clone R35-72, BD Bioscience, San Diego, CA, 
USA) was used to coat a 96-well ELISA plate (ﬂ  at-bottom, 
high-binding, polystyrene; Costar, Corning, NY, USA) at 
4 °C overnight. Next, the plates were washed three times 
with PBS/Tween 20 and incubated with a non-specific 
binding site blocking buffer (1% bovine serum albumin 
in PBS) for 1 h at room temperature. After incubation, the 
plates were again washed three times with PBS/Tween 20 
and serum samples, controls, and standards applied; 1 hr 
incubation at 37 °C followed. Again the plates were washed 
three times and 100 μL per well of biotinylated anti-mouse 
IgE (2 μg/mL; clone R35-118, BD Biosciences) was added 
and the plate incubated for 1 h at room temperature. After 
washing, 100 μL per well of horseradish peroxidase avidin 
D (0.5 μg/mL; Vector Laboratories, Inc, Burlingame, CA) 
was added and the plate incubated at 37 °C for 30 minutes. 
The plates were washed with PBS/Tween 20 ﬁ  ve last times. 
The presence of bound Ab was detected by the addition of 
100 μL per well of o-phenylenediamine dihydrochloride 
(SIGMAFAST™ OPD, Sigma-Aldrich Co., St. Louis, MO) 
and visualized at 405 nm on a microplate reader (VERSAMAX 
Microplate Reader, Molecular Devices, Sunnyvale, CA). 
The Ig contents of the serum samples were compared with 
standard curves generated from the 405 nm absorbance levels 
of known amounts of IgG or IgE.
Statistical analysis
The majority of the data were analyzed using GraphPad 
PRISM (version 4.00; 2003). Data are presented as mean 
values ± standard deviation (SD) and the unpaired Student 
t-test with calculations of a two-tailed p-value were utilized 
to determine signiﬁ  cance; differences with a p-value  0.05 
were considered signiﬁ  cant. Results from the 125I-CCMV, 
125I-HspG41C, and free 125I experiments were evaluated by 
GraphPad PRISM one-way ANOVA to determine statistical 
signiﬁ  cance; differences between the free 125I and 125I-labeled 
cage were evaluated using the Bonferroni’s Multiple 
Comparison Test for multiple post-hoc comparisons. The 
comparisons of percent injected dose/organ for selected 
organs from the 125I-CCMV and 125I -HspG41C experiments 
were made using two-way ANOVA analysis with the GLM 
procedure of SAS (version 8.2; Statistical Analytical Systems 
Institute, Inc., Cary, NC, USA). The main effects of immune 
status (naïve vs. immunized) and time (1 hr vs 24 hr), and 
the interaction between immune status and time were evalu-
ated. When the interaction was not signiﬁ  cant the main effect 
means are reported. If the interaction was signiﬁ  cant, then 
the interaction mean was reported. If the treatment F-test was 
signiﬁ  cant (p  0.05) the treatment least square means were 
separated by the LSD method.
Results
In vivo localization of Texas Red-labeled 
CCMV and HspG41C by ﬂ  uorescence 
microscopy
Genetic variants of both CCMV (CCMV S102C) 
and Hsp (Hsp G41C) were chemically derivatized with Texas 
Red®(TR) in order to visualize the cages by epi-ﬂ  ourescence 
microscopy. Texas Red-labeled CCMV and TR-HspG41C 
cages were intravenously (IV) injected into mice from which 
various tissues were subsequently harvested and evaluated. 
Fluorescent images from vibratome sections of tissues dem-
onstrated TR-HspG41C cages in the lung, liver and kidney 
and TR-CCMV in the liver and kidney at 1 hour post IV 
injection (Figures 1 and 2). Neither the TR-HspG41C nor 
TR-CCMV particles appear to be associated with any one 
cell type in the lung; rather, they were visible on pulmonary 
endothelial surfaces, interstitial perivascular areas, and in 
alveolar lymphatic ducts (Figure 1). The TR-HspG41C 
introduced into the mouse intranasally (IN) appeared rapidly 
in the lymph nodes of the respiratory tract (tracheobronchial 
and cervical lymph nodes) within 1 hour post instillation 
(data not shown). The TR-labeled protein cages appeared 
to freely move in and out among the epithelial cells of the 
airways, the pulmonary endothelial cells, and pulmonary 
draining lymph nodes.
TR-labeled cages were also evident in the sinusoids of 
the mouse liver at 1 hour after IV injection (Figures 1 and 2). 
They appeared to be associated with either phagocytic Kupffer 
cells or endothelial cells of the sinusoid radiating from the 
terminal hepatic venule, but were otherwise evenly dispersed 
throughout the liver. This association of the cages with these 
cell types was not surprising, as both have the capacity to 
interact with particulate materials via phagocytosis, thus 
protecting the systemic circulation by clearing the plasma of 
foreign material (Steffan et al 1986; Dini et al 1995).
As seen in lung and liver, both cage types were present 
in the kidney. One hour after IV injection, cages could be 
seen in the convoluted tubules and interlobular connective 
tissue of the mouse kidney. By 24 hours post injection cages 
were still visible primarily in the convoluted tubules of the 
kidney (Figure 1), although with less intensity than seen at 
1 hour, and in the cortical lymphatics. In summary, these International Journal of Nanomedicine 2007:2(4) 720
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results indicate that both non-cell targeted CCMV and Hsp 
protein cages can be rapidly found within the lungs, kidneys 
and liver, declining by 24 hours post IV injection.
In vivo biodistribution studies of
125I labeled cage
In order to evaluate the biodistribution of CCMV and Hsp 
cages they were radiolabeled with 125I. Both the CCMV and 
Hsp protein cages were rapidly and broadly distributed to a 
majority of the mouse tissue and organ types. Within 1 hr 
post injection, both the CCMV and Hsp protein cages were 
detected in all examined tissues and organs, with 0.1% or less 
of the injected dose in the brain (Table 1). The biodistribution 
of 125I-HspG41C or 125I-CCMV cages in naïve mice at the 
1 hour time point did not signiﬁ  cantly differ from one another 
in terms of percent injected dose/gram of tissue (%ID/g), 
with the exception of the salivary gland (Figure 3). The 
salivary gland of mice injected with 125I-HspG41C had 56% 
greater %ID/g of tissue than the 125I-CCMV injected mice. 
The ﬁ  ve sites of greatest deposition for the 125I-HspG41C or 
125I-CCMV cages at 1 hour were the bladder, thyroid, liver, 
spleen, and salivary gland. Thus, independent of protein cage 
size or amino acid composition, a similar pattern of rapid 
biodistribution of both protein cage types to most tissue and 
organ types was observed.
The biodistribution of 125I-labeled cage was evaluated 
in naïve and immunized mice. Overall, by 24 hours post 
injection, both the CCMV and Hsp protein cages had been 
signiﬁ  cantly cleared to a similar extent from most organs in 
naïve mice except the thyroid where levels actually increased 
over 24 hours (Figures 3 and 4; Tables 1 and 2). In general, 
greater than 80% of the recovered labeled protein cages had 
been removed by 24 hrs as compared to 1 hr post injection. 
Even though there was an overall reduction of both protein 
cages, there were signiﬁ  cant differences (p  0.05) in distribu-
tion of the two cage types in the liver, spleen and kidney, such 
that a greater %ID/g of liver, spleen and kidney was found in 
125I-CCMV versus 125I-HspG41C injected mice. It was evident 
the majority of the 125I-HspG41C or 125I-CCMV cages protein 
cages were secreted through the urine and feces (56%–66% of 
dose) (Table 2). These results demonstrated that independent 
of protein cage type, size or amino acid composition, a similar 
pattern of rapid removal of both protein cages from most tissue 
and organ types in naive mice was observed.
The CCMV and the Hsp protein cages demonstrated 
similar biodistribution patterns in both naïve and immunized 
mice. Similar to the biodistribution patterns observed in 
naive mice, both the CCMV and the Hsp protein cages were 
detected in all tissue and organ types except the brain in 
immunized mice. When 125I-HspG41C or 125I-CCMV protein 
cages were administered IV to mice previously immunized 
with either the Hsp or CCMV protein cages, the distribu-
tion pattern at 1 hour was similar for both types of protein 
cages expressed as either a percentage of dose per gram of 
tissue or per organ basis (Figures 3 and 4; Tables 1 and 2). 
Two exceptions to this were the %ID of 125I-CCMV found 
per gram of both lung and kidney of immunized mice dif-
fered signiﬁ  cantly from the %ID of 125I-HspG41C injected 
in those tissues (p  0.05). In immunized mice at 1 hr, the 
%ID/gm of lung found in mice receiving iodinated HspG41C 
cage was 4.5 times greater than that in the lungs of mice 
receiving iodinated CCMV (30.8% ID/g versus 6.8% ID/g) 
(Table 2 and Figure 3). Conversely, a comparison of the 
%ID/g of kidney indicated a greater amount (1.4 times) of 
iodinated cage present in CCMV-immunized mice than in 
HspG41C-immunized mice at 1 hour.
When the biodistribution of labeled cages was examined 
on a per total organ basis, the pattern of deposition of the two 
types of nanocages among mice organs at 1 and 24 hours was 
similar (p > 0.05) (Figure 4). With regards to naïve versus 
immunized mice, the distribution of nanocages in the whole 
organs was similar with the exception of the liver and GI tract. 
At 1 hour, the 125I-HspG41C IV administered naïve mice had 
approximately 2 times more of the injected dose in the GI 
tract than the Hsp-immunized mice, while the CCMV-naïve 
mice had 2.5 times more cage associated counts in the GI 
tract than CCMV-immunized mice. The opposite was true 
for the %ID in the liver; at 1 hour 2.8 times more of the 125I-
HspG41C dose and 1.6 times more of the 125I-CCMV dose 
was found in the liver of immunized versus naïve mice. The 
%ID/g of thyroid was appreciably less at the 1 hour time 
point in immunized versus naïve mice for 125I-HspG41C or 
125I-CCMV cage (p  0.05; 3.5 and 22.3 times less respec-
tively) (Figure 3).
In order to test the possibility of free 125I release from 
the radiolabeled protein cages skewing the distribution, an 
investigation into the biodistribution of free 125I in mice using 
identical methods to those used in the protein cage biodis-
tribution was conducted. The biodistribution of free 125I was 
notably different than the biodistribution of the injected 
iodinated protein nanocages. The results of the free 125I study 
indicated that at 1 hour post injection the majority of free 125I 
was found in the tegument (24.6 % ID) and gastrointestinal 
tract (16.44 %ID). The organs associated with the highest 
%ID/g of tissue were the thyroid and bladder (221.3% and 
208.9%/g tissue respectively). Gamma counts obtained from International Journal of Nanomedicine 2007:2(4) 721
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Figure 1 Epiﬂ  uorescence microscopy images exhibiting Texas Red-Labeled HspG41C in various mouse tissue vibratome sections after IV instillation of 50–100 μg protein. 
(a) Lymphatic duct ﬁ  lled with particles surrounding an alveolar airway at 1 hour (200x original magniﬁ  cation). (b) Pulmonary arteriole at 1 hour post injection (50 μg Protein) 
with speciﬁ  c ﬂ  uorescence visible on the endothelial surface and perivascular areas of the interstitium (note arrows). (c) Pulmonary airway at 1-hour – pointing to particles 
situated on the endothelial surface and intersititially (100x original magniﬁ  cation). (d) Hepatic lobule at 30 minutes after instillation – terminal hepatic venule with radiat-
ing sinusoids and HspG41C-Texas Red ﬂ  uorescene most likely associated with Kupffer cells (note arrows; 200x original magniﬁ  cation). (e) Frontal sections of the kidney at 
24 hours post injection – interlobular capillary and cortical lymphastics satiated with ﬂ  uorescent labeled cage (100x original magniﬁ  cation). (f) Kidney frontal sections at 1 hour 
demonstrating ﬂ  uorescence in the convoluted tubules and interlobular connective tissue (100x original magniﬁ  cation).International Journal of Nanomedicine 2007:2(4) 722
Kaiser et al
the 24 hour collection of urine were high as well (63.7%ID, 
74.28% of dose recovered) (Figure 5). The presence of free 
125I- in the lungs of injected mice had less %ID/g of tissue 
than the 125I-HspG41C-immunized injected mice at 1 hour 
(5.03% vs 30.78%; p  0.05). The %ID/g of liver and spleen 
at 1 and 24 hours was signiﬁ  cantly less (p  0.05) in free 
125I-injected mice compared to mice injected with 125I-labeled 
cage (Figure 5). One-way ANOVA analysis revealed a sig-
niﬁ  cant difference at the 1 and 24 hour time points (p  0.05) 
when the distribution of 125I-HspG41C or 125I-CCMV in the 
thyroids of naïve and immunized mice were compared to 
free 125I injected mice; immunized mice receiving iodinated 
HspG41C or CCMV had less %ID/g of thyroid than mice 
receiving free 125I alone (Figure 5).
In general, the biodistribution of two different protein 
nanocages in the organs and tissues of naïve or immunized 
mice were similar, both at 1 and 24 hours post injection. 
As well, no real pattern of preferential accumulation in one 
tissue or organ type was readily apparent, with the possible 
exception of the thyroid and liver.
Excreted form of IV injected 125I-labeled 
CCMV and Hsp protein nanocages
in mouse urine
Both cage types (125I-HspG41C and 125I-CCMV) were nearly 
completely cleared from mouse tissues by 24 hours. The total 
percent of injected dose recovered in the urine alone ranged 
from 51% to 60%; from the feces and urine combined values 
were 56.6%–63.3%, while the total recovered dose ranged from 
64% to 89% and none of these were signiﬁ  cantly different.
Various analyses were conducted to determine the form of 
the excreted cage in the urine. In this regard, direct visualiza-
tion of viral concentrates of urine samples (100,000 × g viral 
pellet fraction) by transmission electron microscopy failed 
to identify intact virus particles. In addition, enzyme-linked 
immunosorbent assay (ELISA) and western immunoblot 
analysis utilizing CCMV polyclonal antiserum failed to 
detect intact either 28 nm CCMV particles or intact coat 
protein subunits. No evidence was found that CCMV protein 
cages were secreted in the urine intact. Urine samples from 
mice IV injected with TR-HspG41C or TR-CCMV were 
analyzed using a SDS-polyacrylamide gel electrophoresis; 
ﬁ  rst imaged with ﬂ  uorescence and subsequently stained with 
Coomassie Blue. Results, when compared to control urine 
spiked with TR-HspG41C or TR-CCMV, indicated that the 
cages were not intact and coat protein subunits were not 
detected (data not shown). These observations suggest that 
in the 125I-HspG41C or 125I-CCMV injected mice the cages 
were degraded in vivo and excreted in components smaller 
than the cage protein subunits.
Immune and hypersensitivity response
An ELISA was used to analyze serum from immunized mice 
for either HspG41C- or CCMV-speciﬁ  c IgG. Serum samples 
were obtained from mice seven days after receiving two 50 μg 
IV injections two weeks apart. Results indicated animals were 
highly positive for cage protein-speciﬁ  c IgG (data not shown). 
These mice were then used in the 125I-labeled cage biodistri-
bution experiments described above. The CCMV-immunized 
mice, and to a lesser extent HspG41C-immunized mice, 
exhibited signs of distress 5–7 minutes post injection of 
Figure 2 Fluorescence microscopy displaying Texas Red-labeled CCMV cage in mouse 
liver and kidney at 1 hour post IV instillation of 50μg protein. (a) Hepatic lobule 
with terminal hepatic venule and radiating sinusoids ﬁ  lled with CCMV Texas Red-
labeled particles most likely associated with Kupffer cells (note arrows; 100x original 
magniﬁ  cation). (b) Kidney frontal sections at 1 hour exhibiting Texas Red labeled 
CCMV cage in the convoluted tubules (200x original magniﬁ  cation).
a)
b)International Journal of Nanomedicine 2007:2(4) 723
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Figure 3 Selected organ distribution of 125I-labeled cages on a percent injected dose/gm of tissue basis. (A) Naïve mice receiving 50 μg protein IV injection of either 
125I-HspG41C or 125I-CCMV cage at 1 and 24 hours. (B) Immunized mice receiving 50 μg protein IV injection of either 125I-HspG41C or 125I-CCMV cage at 1 and 24 hours.
(A)
Brain
Heart
Lung
GI tract
Blood
Kidney
Spleen
Salivary Gland
Liver
Thyroid
0
1
0
2
0
3
0
4
0
5
0
Naive 1 hr CCMV
Naive 24 hr CCMV
Naive 24 hr Hsp
50
550
1050
Naive 1 hr Hsp
P
e
r
c
e
n
t
 
I
n
j
e
c
t
e
d
 
D
o
s
e
/
g
r
a
m
 
T
i
s
s
u
e
(B)
Brain
Heart
Lung
GI tract
Blood
Kidney
Spleen
Salivary Gland
Liver
Thyroid
0
1
0
2
0
3
0
4
0
5
0
6
0
Immunized 1 hr CCMV
Immunized 24 hr CCMV
Immunized 24 hr Hsp
60
90
120
Immunized 1 hr Hsp
P
e
r
c
e
n
t
 
I
n
j
e
c
t
e
d
 
D
o
s
e
/
g
r
a
m
 
T
i
s
s
u
e
Naive Mice
CCMV and Hsp Injected
Immunized Mice
CCMV and Hsp InjectedInternational Journal of Nanomedicine 2007:2(4) 725
Biodistribution of protein cage nanoparticles
Figure 4 Percentage of dose per organ in selected tissues. (A) 125I-labeled CCMV and Hsp cage (50 μg protein) tail injected into naïve mice at 1 and 24 hours post 
injection (B) 125I-labeled CCMV and Hsp cage (50 μg protein) tail injected into immunized mice at 1 and 24 hours post injection.
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Table 2 Percent of injected dose/gm of tissue; t-test results
 Cages
Tissue HspG41C  CCMV  K42R
(Mean (n  = 7 for naïve 24 hr mice; n = 8 for immunized   (n = 8)
± SEM)  mice; Salivary gland n = 4 for naïve 1 and 24 hr mice)
  1 hr      24 hr      1 hr      24 hr
  Naïve  Immunized p-  Naïve  Immunized p-  Naïve  Immunized p-  Naïve  Immunized  p-value
     value     value     value     
Liver  20.56  45.73 0.0008  0.59  1.05  0.03  22.79  36.81 0.0006  5.07  3.94  0.05
  ± 3.89  ± 4.45   ± 0.07  ± 0.17  ± 2.63  ± 1.8   ± 0.48  ± 0.17 
Spleen  15.02  13.95 0.79  1.12  0.99  0.68  14.5  10.11 0.05  2.45  1.49  0.006
  ± 2.37  ± 3.05   ± 0.33  ± 0.08  ± 1.65  ± 1.28   ± 0.28  ± 0.1 
Thyroid  132.6 37.52  0.006 483.0  76.39  0.04 193.0 8.66  0.02  126.4 81.61  0.16
  ± 26.99  ± 11.62   ± 184.7  ± 17.13   ± 58.52  ± 1.09   ± 25.63  ± 16.4 
Lung  5.09 30.78  0.0009  0.13  0.24  0.008  4.76 6.82  0.02 0.37 0.15  0.16
  ± 0.41  ± 6.1   ± 0.02  ± 0.03  ± 0.62  ± 0.42   ± 0.15  ± 0.01 
Kidney  7.34  4.43 0.007  0.19  1.79 0.18  9.61  6.21 0.01  1.44  0.43  <0.0001
  ± 0.79  ± 0.5   ± 0.01  ± 0.01  ± 1.15  ± 0.25   ± 0.14  ± 0.01 
Salivary  22.04  16.89 0.42  0.14  0.17  0.58  12.36  11.88 0.82  0.28  0.12  0.004
 Gland  ± 2.96  ± 4.01   ± 0.05  ± 0.02  ± 1.89  ± 0.77   ± 0.04  ± 0.02 
Feces  % of       66.28  56.63  0.09        63.31  59.26  0.09
and Urine   dose     ± 2.3  ± 2.2        ± 3.5  ± 2.3 
   p – values
  1 hr    24 hr
Tissue  Hsp Naive  Hsp Immunized  Hsp Naive  Hsp Immunized
 vs  vs vs  vs
 CCMV  Naivea CCMV  Immunizedb CCMV  Naivec CCMV  Immunizedd
Spleen 0.86  0.26  0.008  0.002
Liver 0.64  0.08  0.0001 <0.0001
Thyroid 0.36 0.03  0.06  0.83
Lung 0.67  0.002  0.16  0.02
Kidney 0.13 0.007  0.0001 <0.0001
Salivary Gland  0.02  0.24  0.08  0.09
Urine and Fecese     0.09  0.09
aComparison of HspG41C naïve vs CCMV K42R naïve mice tissue at 1 hour.
bComparison of HspG41C immunized vs CCMV K42R immunized mice tissue at 1 hour.
cComparison of HspG41C naïve vs CCMV K42R naïve mice tissue at 24 hour.
dComparison of HspG41C immunized vs CCMV K42R immunized mice tissue at 24 hour.
eUrine and Feces were analyzed as percentage of injected dose.
the 125I-labeled cages, including hypopnea, rufﬂ  ed fur, and 
lethargy. Signs of recovery began approximately 1.5 hrs post 
injection and a full recovery was apparent at 2.5 hrs post IV 
administration. Also, the spleens of the 1 hr CCMV injected 
mice were darker in color, the lungs appeared congested, and it 
was difﬁ  cult to obtain the usual 70 μL volume of blood sample 
from the mice after clipping the abdominal aorta.
Immunized mice injected with either HspG41C or CCMV 
nanoparticles under the same conditions as the 125I-injected 
mice did not have any remarkable histological pathology, 
based on observation of liver, kidney or spleen hematoxylin 
and eosin stained sections. However, observations of lung 
sections from CCMV-immunized mice revealed pulmonary 
vascular congestion, which may have accounted for some 
of the respiratory distress observed in these mice. Spleen 
sections from HspG41C- or CCMV-injected mice appeared 
different from each other; areas of white pulp in the 
HspG41C-injected mouse spleen were greater in size with 
well deﬁ  ned germinal centers. Serum samples taken from 
immunized mice prior to challenge with IV cage injections 
were analyzed using an ELISA technique for cage speciﬁ  c 
IgE levels; no IgE was detected (data not shown).
Discussion
These biodistribution studies demonstrated that two different 
protein cage based nanoparticles rapidly translocate exten-
sively and easily throughout mouse tissues after intravenous 
instillation. Fluorescently labeled-HspG41C and CCMV International Journal of Nanomedicine 2007:2(4) 727
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Figure 5 Comparison of selected organs from mice receiving IV free 125I versus mice receiving either 125I-CCMV or 125I-HspG41C cage. (A) Percent of dose/g of lung, 
spleen and liver tissue at 1 and 24 hours. Naïve (N), immunized (I), and free 125I (Free).  (B) Percent of dose excreted in the urine and feces together at 24 hours.
were found in various tissues at different time points as 
evidenced by epiﬂ  uorescence microscopy. The particles 
were visibly associated with the circulatory and lymphatic 
endothelium, pulmonary epithelial surfaces, the interstitium 
of the lung, the outer capsule and perilymphoid zones of the 
spleen (Supplemental Figure 2), the sinusoids of the liver, 
the convoluted tubules of the kidney, and draining lymph 
nodes (Supplemental Figure 3). These results indicate the 
ability of these two different protein-based nanoparticles 
to extravasate from the vascular system to interstitial areas, 
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enter into the lymphatics, possibly return to the circulatory 
system and again appear in interstitial areas of several organs. 
In this regard, ﬂ  uorescently-labeled protein cages given intra-
tracheally quickly traversed the airway epithelium, entered 
the lymphatics of the pulmonary interstitium and could be 
seen in the subcapsular sinus of the lung-associated lymph 
nodes within 15 minutes (data not shown).
The 125I biodistribution data also indicated that both types 
of protein cage nanoparticles rapidly disperse throughout the 
mouse system freely and are not preferentially distributed to 
any particular tissue or organ type. Both types of cages were 
found at similar levels in all tissues and organs tested, except 
the brain. Both the 125I-HspG41C and 125I-CCMV dissemi-
nated in naïve mice in a similar fashion after IV injection. 
This is notable when considering the complete differences in 
amino acid composition, subunit structure and architectures 
and source of the nanocages. Although protein cage size 
differs (12 nm Hsp versus 28 nm CCMV), perhaps this is 
not substantial enough to inﬂ  uence cage distribution in mice. 
In spite of the differences, the two protein cages are similar 
in exterior charge (negative at pH 7.4) and hydrophilicity. 
Surprisingly, iodinated cages injected into mice previously 
immunized to the cages distributed in a similar pattern as 
that observed in naïve mice. The ability of these nanocages 
to distribute widely is highlighted by studies using different 
routes of administration. In separate trials (data not shown), 
50 μg iodinated HspG41C was instilled into mice intrana-
sally and organs taken at 1 and 24 hours. In the lungs of the 
1 hour mice 5.3% ID was recovered, which differs, but not 
greatly, from the IV instilled mice (0.8%–1.4% ID). The 
pulmonary architecture is such that numerous surface areas 
facilitate adherence of inhaled particulate; so it is surprising 
that a greater deposit of nanocage is not seen considering 
that one dose was instilled directly into the lungs and the 
other intravenously. A nanoparticle drug delivery system 
with the ability to move rapidly throughout several tissue 
types may lend to the quick arrival of a therapeutic dose to 
a site not easily accessed by conventional medicinal delivery 
systems.
The high percentage of nanoparticles excreted at 24 hours 
(57%–73% ID) for both cage types in naïve and immunized 
mice is striking. The percentage of cage excreted did not sig-
niﬁ  cantly differ (p = 0.09) among the naïve versus the immu-
nized mice. The ﬁ  ltration system of the kidney is such that 
large molecules encounter barriers of size, electrical charge, 
and molecular conﬁ  guration before they are excreted. Nor-
mally, transport of molecules through this system excludes 
highly negatively charged particles and/or molecules with 
greater than 68,000 MW (Young et al 2006). This suggests 
the both the CCMV and the Hsp protein cages are being 
degraded prior to excretion in the urine. Further experimen-
tation is required to determine the nature, mechanism(s), 
and consequence of potential release of therapeutic agents 
from the interior of the protein caused by possible protein 
cage degradation in vivo. Ultimately, genetic and chemical 
modiﬁ  cation of protein cage architectures may be necessary 
to tailor the degradation characteristics of a particular protein 
cage nanostructure for optimal medical applications.
The % ID in the feces ranged from 5.9% to 7.3% and 
warrants consideration of hepatic circulation and bile com-
position. Bile produced by the parenchymal cells of the 
liver is composed of conjugated bile salts, phospholipids, 
cholesterol, and soluble proteins transcytosed across the 
hepatocyte from the plasma to the bile (Crawford 1996). 
Cholangiocytes, the epithelial cells that line the bile duct, 
secrete and transport proteins from the plasma into the bile; 
ie, sugar, amino acids, IgA, and other cytokines (Prall and 
LaRusso 1999). It is feasible that the iodinated protein cages 
may have crossed into the bile that was secreted into the upper 
duodenum then passed through the colon and were elimi-
nated in the feces. Another plausible explanation is that the 
125I-labeled nanocages traversed across the airway mucosa, 
moved up the muco-ciliary escalator, and were swallowed 
by the mouse and transmitted through the digestive system. 
In this regard, capsids injected IV into mice were seen within 
airway lumina within minutes of injection. Overall, the rapid 
clearance of the particles within a 24 hour period again high-
lights the ability of both HspG41C and CCMV to swiftly 
scatter throughout the whole body without overt retention 
in any particular organ or cell type and then readily clear via 
the renal and fecal routes within 24 hours with no obvious 
morbidity or mortality. The ability of these nanocages to 
quickly exit the body, especially if they can be maintained 
as intact protein cage architectures, could potentially lessen 
the detrimental side effects of dose molecules associated 
with delivery vehicles that did not interact with a targeted 
tissue or decrease excessive exposure in the body of imaging 
agents delivered on either of these platforms.
The lack of signiﬁ  cant differences in biodistribution of 
both types of cage structures between naïve and immunized 
mice may be the function of nanoparticle size. Even though 
no organ type was highly associated with either type of 
protein cage deposition, the liver and spleen were among 
the organs with the highest %ID/g of tissue at 1 hour in both 
naïve and immunized mice. Often times small size particles 
(100 nm) have decreased opsonization and slower recogni-International Journal of Nanomedicine 2007:2(4) 729
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tion by macrophages resulting in their ability to readily evade 
detection and elimination by the reticuloendothelial (RES) 
system (Moghimi 2001; Rossin 2005). An exception to the 
general biodistribution pattern is the change in biodistribution 
in the lung and liver between naïve and immunized mice. 
In the naïve 125I-HspG41C and 125I-CCMV injected mice 
the %ID/g of lung tissue ranged from 4.8 to 5.1% at 1 hour. 
However, in the case of the immunized mice the %ID/g of 
lung was 30.8 and 6.8% respectively at 1 hr. As well, in 
HspG41C or CCMV immunized mice, the %ID/g of liver was 
greater at 1 hour compared to mice not previously exposed to 
the nanocages (122% and 62% greater, respectively). Con-
ceivably, the elevated percent dose in the liver and lung of 
immunized mice was due to the rapid formation of antibody-
cage complexes and trapping by the mononuclear phagocyte 
system (ie, RES). Moreover, previous work that examined the 
biodistribution of free 125I determined that the iodine-tyrosine 
bond is susceptible to hydrolysis by diodinase enzymes that 
are abundant in hepatocyte microsomes (Awasthi et al 2004). 
Iodine is absorbed in the GI tract gastric mucosa, the ductal 
cells of mouse parotid glands, submandibular glands, and 
follicular cells of the thyroid gland via a transmembrane 
sodium/iodine-symporter (Josefsson et al 2002). Therefore, it 
is plausible that in the case of the immunized mice, antibody-
cage complexing captured in the sinusoidal compartment 
of the liver prevented the diodinase enzyme from working 
effectively in the microsomal compartment of the hepatocyte. 
This may offer an explanation for the greater distribution 
of the cage in immunized mice livers and in the case of 
the HspG41C-immunized mice, a lesser amount of cage 
in the salivary gland as compared to naïve mice at 1 hour. 
Furthermore, possibly more antibody-complexed CCMV 
cage lingered in the liver and spleen of immunized mice at 
24 hours than did antibody-complexed HspG41C.
Intravenous administration of CCMV and Hsp in mice did 
not appear to be overtly harmful. Both the CCMV and Hsp 
protein cage nanoparticles were immunogenic as indicated 
by production of a strong IgG and IgM response. However, 
there were no signiﬁ  cant differences in mouse body weight 
or appearance between naïve or immunized mice over a 
21-day period (data not shown). In both naïve and immunized 
mice there was not a drastically altered biodistribution or 
excretion pattern of either the 125I-HspG41C or 125I-CCMV 
particles. However, IV administration of 125I-HspG41C or 
125I-CCMV injected mice into immunized mice did produce 
temporary adverse responses, which are not uncommon in 
IV-administered therapeutics (Allen and Cullis 2004). How-
ever, like QDs and other protein-based therapeutic agents, 
problematical side effects might very well be overcome by 
protein cage modiﬁ  cations such as covalently linking poly-
ethylene glycol (PEG) chains to exterior surface. Clearly, 
complete toxicology studies need to be performed to fully 
asses the mammalian biocompatibility of protein cage based 
therapeutic platforms.
Our results differ from those analyzing the biodistribution, 
circulation half-life and in vivo compatibility of ﬂ  uores-
cently labeled Cowpea mottle viruses (CPMV) (Rae et al 
2005; Lewis et al 2006). Compared to the results described 
herein utilizing CCMV, CPMV distributed in relatively 
higher amounts in the spleen, lymph nodes, kidney, liver 
and intestinal tract of the mice at day 1 post injection and 
in some cases increased in deposition in the organs over 
time (24 and 72 hours post injection). In contrast, both the 
CCMV and Hsp protein cage architectures were nearly 
completely eliminated from animals by 24 hours post 
injection. The CPMV particles were found in the paren-
chyma of the brain in mice receiving particles via the oral 
and intravenous routes (Rae et al 2005), yet in our studies 
the distribution of CCMV in the brain was not detected. 
Chick chorioallantoic membrane modeling has been used to 
demonstrate the usefulness of CPMV delivered ﬂ  uorescent 
imaging dyes and it was found that CPMV localized to 
vascular endothelium (Lewis et al 2006). The 125I-CCMV 
results from this study indicated that our nanoparticles 
were associated with vascular endothelium as well as local-
ized interstitially, which is speculated to be the results of 
nonprofessional phagocytes such as liver and pulmonary 
endothelial cells (Steffan et al 1986; Dini et al 1995; Chen 
et al 2006) that engulfed the 125I-CCMV. The CCMV and 
CPMV are similar in that both are ∼28 nm particles with 
T = 3 icosahedral symmetry, they both have similar eight 
stranded β-barrel folds of the coat protein subunits that 
comprise the protein shell of their virus particle, and they 
can both systemically infect similar host plants. However, 
there is little amino acid similarity between the CCMV and 
CPMV coat proteins which may contribute to the observed 
biodistribution differences between the two nanoparticles. 
In addition, differences in particle structure may also alter 
how each type of particle interacts in mice. The observed 
differences between CCMV and CPMV nanoparticles rein-
forces the notion that it is difﬁ  cult to predict how seemingly 
very similar nanopartices will behave in vivo.
There are many parallels and differences between the 
biodistribution characteristics of viral and non-viral protein 
based nanoparticles and QDs. In general, IV administration of 
both types of nanoparticles results in broad tissue and organ International Journal of Nanomedicine 2007:2(4) 730
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distribution within tested animals. Both are not overtly toxic 
to animals and surface modiﬁ  cations (eg, pegylation) (Owens 
and Peppas 2006) can be used to tailor their biocompatibility 
properties for applications in medicine. In contrast to QDs, 
the protein cage nanoplatforms examined here did not pref-
erentially accumulate and persist within mice tissues and 
organs (especially the liver), providing a potential beneﬁ  t 
as therapeutic and imaging agents. However, in comparison 
to QDs, both the CCMV and Hsp protein cages are likely 
more immunogenic, indicating that immunological response 
to each type of protein cage platform will have to be fully 
addressed and tailored before they will ﬁ  nd broad applica-
tion in medicine.
This work contributes fundamental baseline information 
on the biocompatibility of protein cage nanoplatforms. The 
broad distribution and movement through tissues, the rapid 
excretion, and a lack of preferential distribution may render 
possible advantages for the use of Hsp or CCMV as safe, 
biocompatible, nanoplatforms for applications in medicine 
and support the need for further in vivo investigation into 
the application of protein based nanocages as therapeutic 
and imaging platforms.
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Supplemental Figure 1 Characterizations of HspG41C, HspG41C-GFE, and CCMV K42R Before (A, C, E) and After (B, D, F) Iodination.
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Biodistribution of protein cage nanoparticles
a) b)
Supplemental Figure 2 Epiﬂ  uorescence microscopy displaying Texas Red-labeled HspG41C cage in mouse spleen at 30 minutes post IV instillation of 105 μg protein. 
(a) Transverse cryostat spleen section; labeled particles appear in the red pulp surrounding the periarterial lymphoid sheaths (200x original magniﬁ  cation). (b) Same tissue 
at higher magniﬁ  cation (400x original).
Supplemental Figure 3 Fluorescently labeled HspG41C particles identiﬁ  ed in 
lung-associated lymph nodes. Epiﬂ  uorescence microscopy views of a tracheobron-
chial lymph node excised from a mouse at 3 hours after IV instillation of 50 μg 
Texas Red-HspG41C (40x original magniﬁ  cation).